ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / ETF / Index / XBI / forecast
XLRE (63) ITA (47) ARKK (53) XLB (67) ⌘ Pro Terminal →

SPDR S&P Biotech ETF (XBI) 12-Month Stock Forecast & Price Target Cone

$152.05 -1.16% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $151.44

SPDR S&P Biotech ETF (XBI) earns a Roarable Rating of C (Hold) with 65/100 RQD Confidence. As an exchange-traded fund, single-company GAAP gross margins, Altman-Z, and CEO Form 4 insider metrics are N/A for fund structure; its score reflects basket trend, institutional flow, and macro regime alignment.

ROARABLE C • HOLD / WATCH Cap $7.40B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XBI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XBI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, SPDR S&P Biotech ETF (NYSE: XBI) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $152.05 (-1.16% 1D, market cap $7.40B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 11/20. Across 40 tracked ETF / Index issuers, XBI ranks #15 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XBI compare to XLRE and ITA in the ETF / Index sector?
▼

Within the ETF / Index sector (Equal-Weight Clinical Biotech), XBI carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of N/A (ETF), and ROIC of N/A (ETF). By comparison, XLRE (Real Estate Select Sector SPDR Fund) holds a C grade (63/100 RQD, P/E N/A, ROIC —, cap $8.00B) and ITA (iShares U.S. Aerospace & Defense ETF) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $6.80B). Among the 5-stock peer group, XBI leads on earnings multiple (N/A) while XBI leads on capital efficiency (— ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XBI?
▼

For SPDR S&P Biotech ETF (XBI), key quantitative strengths include Diversified Equal-Weight Clinical Biotech basket eliminates single-company earnings blowup risk and Deep intraday secondary-market liquidity with transparent underlying index holdings., while primary risk factors center on Corporate GAAP gross margin, Altman-Z, and Form 4 insider metrics are N/A for ETF fund structures and Underlying index basket remains sensitive to Federal Reserve liquidity and Treasury yield swings.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $151.44 (-0.40%)🧬 ETF Open-End Share Creation/Redemption⚙️ Cash Engine: 18/20 (A) • Liquid Basket
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510065
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C
Fund (18)Whales (11)Struct (15)Macro (10)Flow (11)
Each axis scored 0–20
12M PRICE TARGET CONE+3.2% Base Target
$185 Bull$157 Base$122 Bear
📬 FREE XBI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XBI)Realized 20D OHLCV Swing Band: ±5.5%
Deterministic 5-Pillar Attribution (65/100 Composite)
🔍 WHY XBI SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (28% of score)

ETF liquidity & tracking efficiency ($7.40B AUM)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (23% of score)

Diversified basket structure mitigates single-issuer 10-K restatement risk

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (47) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
57
Grade C$146.77+4.1% Next Q
Q2 (-2Q)
60
Grade C$152.78+3.1% Next Q
Q3 (-1Q)
62
Grade C+$157.51-3.5% Next Q
Current
65
Grade C$152.05+1.3% Hist 90D α
Trajectory: C (57) → C (65)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the XBI Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, XBI faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Corporate GAAP gross margin, Altman-Z, and Form 4 insider metrics are N/A for ETF fund structures.

⚠️ Forensic Kill-Switch #2

Underlying index basket remains sensitive to Federal Reserve liquidity and Treasury yield swings.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($155.90) or 200D SMA ($142.09) invalidates the momentum regime and cuts Target Base ($156.84) toward Bear Floor ($122.34).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XBI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XBI Beats Next Quarter EPS Consensus (Quarterly Rebalance / Distribution) & Holds Above 200D SMA”
YES 65%NO 35%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your XBI Position Size: $10,000

Shares at $152.05: 65.8 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $122.34
$8,046
$-1,954 (-19.5%)
12M Consensus BaseTarget $156.84
$10,315
+$315 (+3.2%)
12M Bull Case BreakoutTarget $185.07
$12,172
+$2,172 (+21.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$16374%A
Goldman SachsSector Coverage LeadBUY$17469%B
JP MorganUS Large-Cap ResearchHOLD$14058%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (XBI Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
XBI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.90%📐 HORIZONTAL RANGE
2026-11-03O $153.9H $153.9L $152.1C $152.1VOL 9.08M
RES: $159.5SUP: $143.9SMA50: $155.9SMA200: $142.1
$173.8$157.5$141.2$124.9$108.6RES $159.5SUP $143.9$152.12026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XBI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XBI Butterfly Map → + Track XBI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
ETF / Index Composite — N/A for Fund Structure

Single-issuer corporate Reverse-DCF growth hurdles do not apply to index funds or ETFs.

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on XBI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XBI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XBI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XBI)

ETF / Index Rank #15 of 40 ⚔️ XLRE vs XBI Full Matrix →

1. Head-to-Head ETF / Index Peer Comparison (XBI vs. XLRE, ITA, ARKK, XLB)

Industry: Equal-Weight Clinical Biotech (1 Tracked Issuers)

Across 40 tracked ETF / Index securities in the Roarable RQD universe, SPDR S&P Biotech ETF (XBI) ranks #15 by composite RQD confidence (65/100, grade C) and #31 by equity capitalization ($7.40B). Within this direct 5-issuer industry benchmark cohort, XBI leads on earnings valuation at N/A trailing P/E, while XBI leads on capital efficiency and profitability with ETF composite structure and benchmark tracking. XLB currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with XBI at 65/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XBI ACTIVE
SPDR S&P Biotech ETF
C 65/100 — — — -1.16% $7.40B Benchmark Subject
XLRE
Real Estate Select Sector SPDR Fund
C 63/100 — — — +0.25% $8.00B /xlre-vs-xbi →
ITA
iShares U.S. Aerospace & Defense ETF
D 47/100 — — — -2.17% $6.80B /ita-vs-xbi →
ARKK
ARK Innovation ETF
D+ 53/100 — — — -6.46% $6.50B /arkk-vs-xbi →
XLB
Materials Select Sector SPDR Fund
C+ 67/100 — — — +0.40% $6.00B /xlb-vs-xbi →

2. XBI ETF Structure, Technical Regime & Benchmark Role Breakdown

EXCHANGE-TRADED FUND / COMPOSITE VEHICLE • NYSE

Because SPDR S&P Biotech ETF (XBI) is structured as an exchange-traded fund / composite basket rather than a single operating corporation filing 10-K GAAP income statements, Roarable evaluates XBI on technical trend regime, moving-average dispersion, 52-week range positioning, relative strength (RSI-14), and secondary-market share volume liquidity. At $152.05, XBI trades vs. its 50-day SMA of $155.90 and 200-day SMA of $142.09 on daily liquidity of 9,076,907 shares.

50D SMA Level
$155.90
Medium-Term Trend Anchor
200D SMA Level
$142.09
Institutional Secular Line
52-Week Range Pos
72.0%
$106.30 – $169.89
RSI-14 Momentum
47.0
NEUTRAL RANGE
Volume Liquidity
9,076,907
AUM Cap $7.40B

3. XBI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XBI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SPDR S&P Biotech ETF (NYSE: XBI) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $152.05 (-1.16% 1D, market cap $7.40B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 11/20. Across 40 tracked ETF / Index issuers, XBI ranks #15 in composite RQD confidence.

How does XBI compare to XLRE and ITA in the ETF / Index sector?

Within the ETF / Index sector (Equal-Weight Clinical Biotech), XBI carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of N/A (ETF), and ROIC of N/A (ETF). By comparison, XLRE (Real Estate Select Sector SPDR Fund) holds a C grade (63/100 RQD, P/E N/A, ROIC —, cap $8.00B) and ITA (iShares U.S. Aerospace & Defense ETF) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $6.80B). Among the 5-stock peer group, XBI leads on earnings multiple (N/A) while XBI leads on capital efficiency (— ROIC).

What are the biggest fundamental strengths and SEC risk factors for XBI?

For SPDR S&P Biotech ETF (XBI), key quantitative strengths include Diversified Equal-Weight Clinical Biotech basket eliminates single-company earnings blowup risk and Deep intraday secondary-market liquidity with transparent underlying index holdings., while primary risk factors center on Corporate GAAP gross margin, Altman-Z, and Form 4 insider metrics are N/A for ETF fund structures and Underlying index basket remains sensitive to Federal Reserve liquidity and Treasury yield swings.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XBI trading relative to its 50-day, 200-day, and 52-week technical levels?

XBI last traded at $152.05 (-1.16% on volume of 9,076,907 shares), positioning the stock -2.47% below its 50-day simple moving average ($155.90) and +7.01% above its 200-day simple moving average ($142.09). Across its 52-week range of $106.30 to $169.89, XBI sits at the 71.9% percentile with a 14-day RSI of 47.0 (NEUTRAL RANGE) and an implied next-earnings move of ±5.5% ($143.69 to $160.41).

Direct Sub-Reports: XBI RQD Cockpit XBI 12M Forecast XBI Earnings & Move XBI Dividends & DRIP XBI Insiders & 13F XBI Whale Options XBI Profit Sankey XBI News & Why
ROARABLE RATING BRIEF • RQD 65/100 (C) ✓ SEC XBRL & RQD VERIFIED

XBI — SPDR S&P Biotech ETF: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

SPDR S&P Biotech ETF (XBI) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $152.05 (-1.16% 1D, market capitalization $7.40B).

  • Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (15/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Is a liquid institutional exchange-traded fund listed on NYSE, classified under Sector: ETF / Index and Industry: Equal-Weight Clinical Biotech. It tracks that equal-weight clinical biotech segment and is described as having approximately $7.4B in assets under management. Revenue, customers, and fee structure are not described in the source data, so the fund's sales and monetization model cannot be detailed beyond its index-tracking purpose.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 65/100): Diversified Equal-Weight Clinical Biotech basket eliminates single-company earnings blowup risk. Deep intraday secondary-market liquidity with transparent underlying index holdings. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $106.30 – $169.89 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Corporate GAAP gross margin, Altman-Z, and Form 4 insider metrics are N/A for ETF fund structures. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply_chain is NONE, butterfly_links is empty, and proprietary_signals is empty. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are supplied in the source data.

  • Key Question #1: Can XBI sustain or expand its — operating margin and — ROIC against Equal-Weight Clinical Biotech peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $169.89 52-week high?
  • Key Question #3: How sensitive is XBI's equity valuation to ETF / Index capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

XBI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SPDR S&P Biotech ETF (XBI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XBI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XBI Bull vs. Bear Conversation Board — What's Your Call at $152.05?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XBI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on XBI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $196.14 (+29.0%)
📌 Pinned Debate

Roarable rates XBI a B (72) with a 19/20 fundamental pillar and a 16/20 forensic balance sheet (Altman Z 2.5, Piotroski 6/9, Debt/Equit

The street is overcomplicating SPDR S&P Biotech ETF (XBI). Roarable rates XBI a B (72) with a 19/20 fundamental pillar and a 16/20 forensic balance sheet (Altman Z 2.5, Piotroski 6/9, Debt/Equity 0.5), supporting a Good Risk/Reward verdict.. With an RQD score of 65/100 (C) and Forensic Balance Sheet at 15/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $164.21.

EarningsSniper 🐂 BULL

Both sides have a point here — XBI's 15/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $118.60 (-22.0%)
Spot @ $152.05

The rating's strongest pillar cites ROIC 0% and FCF yield 0%, while the macro pillar scores only 10/20 on beta 1.0 and sector sensitivi

Careful chasing XBI at $152.05. The rating's strongest pillar cites ROIC 0% and FCF yield 0%, while the macro pillar scores only 10/20 on beta 1.0 and sector sensitivity, leaving the fund exposed to sector-wide moves with no earnings-based valuation available.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $118.60 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%